Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Cash-to-Debt : 0.10 (As of Jan. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cotinga Pharmaceuticals's cash to debt ratio for the quarter that ended in Jan. 2020 was 0.10.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Cotinga Pharmaceuticals couldn't pay off its debt using the cash in hand for the quarter that ended in Jan. 2020.

The historical rank and industry rank for Cotinga Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

COTQF's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.39
* Ranked among companies with meaningful Cash-to-Debt only.

Cotinga Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Cotinga Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cotinga Pharmaceuticals Cash-to-Debt Chart

Cotinga Pharmaceuticals Annual Data

Trend

Apr10

Apr11

Apr12

Apr13

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

1.13

Cotinga Pharmaceuticals Quarterly Data
	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	1.13	0.24	0.10	0.10

Competitive Comparison of Cotinga Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Cotinga Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cotinga Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cotinga Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cotinga Pharmaceuticals's Cash-to-Debt falls into.

Cotinga Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cotinga Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Apr. 2019 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.168	/	(0.149	+	0)
	=	1.13

Cotinga Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Jan. 2020 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.035	/	(0.359	+	0)
	=	0.10

Cotinga Pharmaceuticals (OTCPK:COTQF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Cotinga Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1

Website

http://www.cotingapharma.com

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results

By GlobeNewswire GlobeNewswire • 04-03-2018

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire • 05-22-2019